Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-58,200
Closed -$16.8M 71
2023
Q4
$16.8M Buy
58,200
+22,000
+61% +$5.99M 0.62% 48
2023
Q3
$9.73M Buy
+36,200
New +$9.03M 0.31% 78
2023
Q2
Sell
-161,500
Closed -$39M 83
2023
Q1
$39M Buy
161,500
+30,400
+23% +$7.46M 1.29% 29
2022
Q4
$34.4M Buy
+131,100
New +$35.1M 1.15% 31

Other funds holding AMGN

Braidwell's AMGN Position: Q1 2024 in Review

Braidwell sold out of Amgen (AMGN) in Q1 2024, closing a stake of 58,200 shares — an estimated $16.8M sold.

Braidwell first reported a position in AMGN in Q4 2022 and held it in 4 quarters. The position peaked at $39M in Q1 2023. 2,721 funds tracked by Wall St. Rank hold AMGN as of Q1 2024.

  • Braidwell reported no remaining Amgen position as of Q1 2024 after selling out during the quarter.
  • Braidwell sold 58,200 Amgen shares in Q1 2024, an estimated $16.8M.
  • Braidwell first reported a position in Amgen in Q4 2022 and held it in 4 quarters.
  • Braidwell's Amgen position peaked at $39M in Q1 2023.
  • 2,721 funds tracked by Wall St. Rank held Amgen as of Q1 2024.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.